{"transactions":[{"id":894020,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-19T20:57:12.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":45559,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer."}],"balance_after":86887,"source":{"system":"sec-edgar","filing":"0001570562-26-000020","document":"wk-form4_1771552629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056226000020/wk-form4_1771552629.xml","form_type":"4"}},{"id":1036593,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33450,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.51,"expiration_date":"2035-06-30","underlying":"Common Stock","underlying_shares":33450},"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1036592,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14545,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":12.01,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":14545},"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1036591,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13950,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":8.13,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":13950},"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1036590,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2032-07-15","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1036589,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":37.53,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1036588,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":48.67,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1036587,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":21.45,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1036586,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":11.16,"expiration_date":"2028-04-24","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1036585,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25080,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1036584,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-18T21:27:10.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5825,"price":8.6,"value":50095.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the \"Merger Consideration\"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the \"Effective Time\"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001106519-25-000005","document":"form4-09192025_010905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110651925000005/form4-09192025_010905.xml","form_type":"4"}},{"id":1096075,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-07-02T16:20:15.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":33450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer on each vesting date, and are exercisable immediately upon vesting."}],"balance_after":33450,"derivative":{"exercise_price":4.51,"expiration_date":"2035-06-30","underlying":"Common Stock","underlying_shares":33450},"source":{"system":"sec-edgar","filing":"0001415889-25-019046","document":"form4-07022025_040710.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000141588925019046/form4-07022025_040710.xml","form_type":"4"}},{"id":1096074,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T16:20:15.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":25080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2026, subject to the Reporting Person's continued service to the Issuer on the vesting date."}],"balance_after":30905,"source":{"system":"sec-edgar","filing":"0001415889-25-019046","document":"form4-07022025_040710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000141588925019046/form4-07022025_040710.xml","form_type":"4"}},{"id":1213016,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T18:54:08.000Z","date":"2025-03-07","kind":"grant","planned":false,"acquired":true,"shares":11146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":11146,"derivative":{"exercise_price":13.58,"expiration_date":"2035-03-07","underlying":"Common Stock","underlying_shares":11146},"source":{"system":"sec-edgar","filing":"0001570562-25-000039","document":"wk-form4_1741733641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056225000039/wk-form4_1741733641.xml","form_type":"4"}},{"id":1213015,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-11T18:54:08.000Z","date":"2025-03-07","kind":"grant","planned":false,"acquired":true,"shares":7364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of March 7, 2025, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer"}],"balance_after":41328,"source":{"system":"sec-edgar","filing":"0001570562-25-000039","document":"wk-form4_1741733641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056225000039/wk-form4_1741733641.xml","form_type":"4"}},{"id":1481061,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-13T21:00:37.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":14545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer on each vesting date, and are exercisable immediately upon vesting."}],"balance_after":14545,"derivative":{"exercise_price":12.01,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":14545},"source":{"system":"sec-edgar","filing":"0001104659-24-071399","document":"tm2417212-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465924071399/tm2417212-2_4seq1.xml","form_type":"4"}},{"id":1481060,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T21:00:37.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":3495,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2025, subject to the Reporting Person's continued service to the Issuer on the vesting date."}],"balance_after":5825,"source":{"system":"sec-edgar","filing":"0001104659-24-071399","document":"tm2417212-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465924071399/tm2417212-2_4seq1.xml","form_type":"4"}},{"id":1516295,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-15T17:20:08.000Z","date":"2024-05-14","kind":"sale","planned":false,"acquired":false,"shares":6718,"price":12.601,"value":84653.518,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple trades at prices ranging from $12.60 to $12.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":33964,"source":{"system":"sec-edgar","filing":"0001570562-24-000090","document":"wk-form4_1715807991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056224000090/wk-form4_1715807991.xml","form_type":"4"}},{"id":1516294,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-15T17:20:08.000Z","date":"2024-05-13","kind":"sale","planned":false,"acquired":false,"shares":3643,"price":12.7247,"value":46356.0821,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were sold in multiple trades at prices ranging from $12.72 to $12.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":40682,"source":{"system":"sec-edgar","filing":"0001570562-24-000090","document":"wk-form4_1715807991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056224000090/wk-form4_1715807991.xml","form_type":"4"}},{"id":1651939,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-09T18:37:55.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":9377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":9377,"derivative":{"exercise_price":13.15,"expiration_date":"2034-02-07","underlying":"Common Stock","underlying_shares":9377},"source":{"system":"sec-edgar","filing":"0001570562-24-000024","document":"wk-form4_1707521864.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056224000024/wk-form4_1707521864.xml","form_type":"4"}},{"id":1651938,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T18:37:55.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":6464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 7, 2024, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer."}],"balance_after":44325,"source":{"system":"sec-edgar","filing":"0001570562-24-000024","document":"wk-form4_1707521864.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056224000024/wk-form4_1707521864.xml","form_type":"4"}},{"id":1861046,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-06-09T18:01:58.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":13950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on each vesting date and are exercisable immediately upon vesting."}],"balance_after":13950,"derivative":{"exercise_price":8.13,"expiration_date":"2033-06-08","underlying":"Common stock","underlying_shares":13950},"source":{"system":"sec-edgar","filing":"0001104659-23-070043","document":"tm2318348-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465923070043/tm2318348-3_4seq1.xml","form_type":"4"}},{"id":1861045,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T18:01:58.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":2330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2024, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on the vesting date."}],"balance_after":2330,"source":{"system":"sec-edgar","filing":"0001104659-23-070043","document":"tm2318348-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465923070043/tm2318348-3_4seq1.xml","form_type":"4"}},{"id":2040574,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-31T20:41:08.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":11789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":11789,"derivative":{"exercise_price":10.25,"expiration_date":"2033-01-27","underlying":"Common Stock","underlying_shares":11789},"source":{"system":"sec-edgar","filing":"0001570562-23-000021","document":"wf-form4_167521565164195.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056223000021/wf-form4_167521565164195.xml","form_type":"4"}},{"id":2040573,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T20:41:08.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer."}],"balance_after":37861,"source":{"system":"sec-edgar","filing":"0001570562-23-000021","document":"wf-form4_167521565164195.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056223000021/wf-form4_167521565164195.xml","form_type":"4"}},{"id":2205591,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option (right to buy)","published_at":"2022-07-19T13:20:07.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting."}],"balance_after":16000,"derivative":{"exercise_price":16.64,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-22-080790","document":"tm2221312-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465922080790/tm2221312-2_4seq1.xml","form_type":"4"}},{"id":2268615,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T18:49:09.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":5000,"price":13.616,"value":68080.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple trades at prices ranging from $13.50 to $13.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":29568,"source":{"system":"sec-edgar","filing":"0001570562-22-000104","document":"wf-form4_165282765366364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056222000104/wf-form4_165282765366364.xml","form_type":"4"}},{"id":2268614,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T18:49:09.000Z","date":"2022-05-13","kind":"sale","acquired":false,"shares":5313,"price":13.097,"value":69584.361,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were sold in multiple trades at prices ranging from $13.07 to $13.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":34568,"source":{"system":"sec-edgar","filing":"0001570562-22-000104","document":"wf-form4_165282765366364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056222000104/wf-form4_165282765366364.xml","form_type":"4"}},{"id":2425456,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-26T21:01:34.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":22727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":22727,"derivative":{"exercise_price":5.46,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":22727},"source":{"system":"sec-edgar","filing":"0001570562-22-000049","document":"wf-form4_164324887745959.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056222000049/wf-form4_164324887745959.xml","form_type":"4"}},{"id":2425455,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-26T21:01:34.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":15568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 24, 2022, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer"}],"balance_after":39881,"source":{"system":"sec-edgar","filing":"0001570562-22-000049","document":"wf-form4_164324887745959.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056222000049/wf-form4_164324887745959.xml","form_type":"4"}},{"id":2547454,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-10-06T19:41:01.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":78058,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. (\"HoldCo\") pursuant to the Transaction Agreement (the \"Agreement\"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a \"CVR\") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. (\"HoldCo\") pursuant to the Transaction Agreement (the \"Agreement\"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a \"CVR\") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-21-009277","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000117911021009277/edgar.xml","form_type":"4"}},{"id":2549721,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-10-05T19:21:10.000Z","date":"2021-10-01","kind":"tax_withholding","acquired":false,"shares":17763,"price":2.06,"value":36591.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."}],"balance_after":78058,"source":{"system":"sec-edgar","filing":"0001179110-21-009218","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000117911021009218/edgar.xml","form_type":"4"}},{"id":2670609,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option (right to buy)","published_at":"2021-06-14T17:03:07.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting."}],"balance_after":16000,"derivative":{"exercise_price":37.53,"exercise_date":"2021-07-10","expiration_date":"2031-06-10","underlying":"Common stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-21-080831","document":"tm2118093-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465921080831/tm2118093-13_4seq1.xml","form_type":"4"}},{"id":2708636,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-05-18T19:10:07.000Z","date":"2021-05-18","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units, which vest in full on May 18, 2022, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":95821,"source":{"system":"sec-edgar","filing":"0001179110-21-005555","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000117911021005555/edgar.xml","form_type":"4"}},{"id":2710662,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-05-17T18:29:02.000Z","date":"2021-05-14","kind":"tax_withholding","acquired":false,"shares":19075,"price":2.35,"value":44826.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."}],"balance_after":55821,"source":{"system":"sec-edgar","filing":"0001179110-21-005441","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000117911021005441/edgar.xml","form_type":"4"}},{"id":2872559,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T17:13:01.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":19313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer."}],"balance_after":24313,"source":{"system":"sec-edgar","filing":"0001570562-21-000037","document":"wf-form4_161290876572094.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056221000037/wf-form4_161290876572094.xml","form_type":"4"}},{"id":2902688,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option (right to buy)","published_at":"2021-01-20T16:16:17.000Z","date":"2021-01-19","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Stock option granted to the Reporting Person as a non-employee director pursuant to the 2015 Equity Incentive Plan of Y-mAbs Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option was (a) granted on April 24, 2018 pursuant to the 2015 Equity Incentive Plan of Y-mAbs Therapeutics, Inc., and (b) represents the right to purchase a total of 32,000 shares of common stock; and (c) vests and becomes exercisable in equal monthly installments until the third anniversary of the date of grant subject to continued service through such dates and unless vesting is accelerated pursuant to the terms of the grant."}],"balance_after":24000,"derivative":{"exercise_price":11.16,"expiration_date":"2028-04-24","underlying":"Common stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001104659-21-005833","document":"tm211939-2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465921005833/tm211939-2_4.xml","form_type":"4"}},{"id":2902687,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-20T16:16:17.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":2000,"price":46.5226,"value":93045.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $45.9500 to $47.6800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-005833","document":"tm211939-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465921005833/tm211939-2_4.xml","form_type":"4"}},{"id":2902686,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-20T16:16:17.000Z","date":"2021-01-19","kind":"exercise","acquired":true,"shares":2000,"price":11.16,"value":22320.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001104659-21-005833","document":"tm211939-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465921005833/tm211939-2_4.xml","form_type":"4"}},{"id":2971556,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option (right to buy)","published_at":"2020-11-20T16:15:45.000Z","date":"2020-11-18","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Stock option granted to the Reporting Person as a non-employee director pursuant to the 2015 Equity Incentive Plan of Y-mAbs Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option was (a) granted on April 24, 2018 pursuant to the 2015 Equity Incentive Plan of Y-mAbs Therapeutics, Inc., and (b) represents the right to purchase a total of 32,000 shares of common stock; and (c) vests and becomes exercisable in equal monthly installments until the third anniversary of the date of grant subject to continued service through such dates and unless vesting is accelerated pursuant to the terms of the grant."}],"balance_after":26000,"derivative":{"exercise_price":11.16,"expiration_date":"2028-04-24","underlying":"Common stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001104659-20-127957","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465920127957/a4.xml","form_type":"4"}},{"id":2971555,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-20T16:15:45.000Z","date":"2020-11-18","kind":"sale","acquired":false,"shares":2000,"price":45.765,"value":91530.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercise and sale transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $45.2200 to $46.2900. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-127957","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465920127957/a4.xml","form_type":"4"}},{"id":2971554,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-20T16:15:45.000Z","date":"2020-11-18","kind":"exercise","acquired":true,"shares":2000,"price":11.16,"value":22320.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercise and sale transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001104659-20-127957","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465920127957/a4.xml","form_type":"4"}},{"id":2991278,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option (right to buy)","published_at":"2020-11-05T17:51:04.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Stock option granted to the Reporting Person as a non-employee director pursuant to the 2015 Equity Incentive Plan of Y-mAbs Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option was (a) granted on April 24, 2018 pursuant to the 2015 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.,  and (b) represents the right to purchase a total of 32,000 shares of common stock; and (c) vests and becomes exercisable in equal monthly installments until the third anniversary of the date of grant subject to continued service through such dates and unless vesting is accelerated pursuant to the terms of the grant."}],"balance_after":28000,"derivative":{"exercise_price":11.16,"expiration_date":"2028-04-24","underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-20-121930","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465920121930/a4.xml","form_type":"4"}},{"id":2991277,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-05T17:51:04.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":4000,"price":45,"value":180000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercise and sale transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-121930","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465920121930/a4.xml","form_type":"4"}},{"id":2991276,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-05T17:51:04.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":4000,"price":11.16,"value":44640.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercise and sale transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001104659-20-121930","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465920121930/a4.xml","form_type":"4"}},{"id":3021788,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-09-28T07:48:17.000Z","date":"2020-09-24","kind":"purchase","acquired":true,"shares":8000,"price":2.13,"value":17040.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased on the open market in multiple transactions at prices ranging from $2.13 to $2.14,  inclusive. The Reporting Person undertakes to provide to the Issuer, to any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price."}],"balance_after":74896,"source":{"system":"sec-edgar","filing":"0001179110-20-009968","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000117911020009968/edgar.xml","form_type":"4"}},{"id":3037891,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-09-04T16:28:26.000Z","date":"2020-09-03","kind":"tax_withholding","acquired":false,"shares":23104,"price":3.61,"value":83405.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Strongbridge Biopharma plc to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."}],"balance_after":66896,"source":{"system":"sec-edgar","filing":"0001179110-20-009587","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000117911020009587/edgar.xml","form_type":"4"}},{"id":3101080,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option (right to buy)","published_at":"2020-06-24T16:46:46.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting."}],"balance_after":16000,"derivative":{"exercise_price":48.67,"exercise_date":"2020-07-23","expiration_date":"2030-06-23","underlying":"Common stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-20-076457","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465920076457/a4.xml","form_type":"4"}},{"id":3147584,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-05-15T16:47:02.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units, which vest in full on May 14, 2021, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001179110-20-006099","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000117911020006099/edgar.xml","form_type":"4"}},{"id":3303168,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-24T21:07:54.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":23458,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":23458,"derivative":{"exercise_price":10.19,"expiration_date":"2030-01-23","underlying":"Common Stock","underlying_shares":23458},"source":{"system":"sec-edgar","filing":"0001570562-20-000038","document":"wf-form4_157991805639271.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056220000038/wf-form4_157991805639271.xml","form_type":"4"}},{"id":3359139,"issuer":{"id":72980,"kind":"organization","name":"STRATA Skin Sciences, Inc.","symbol":"SSKN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true}}],"security":"SSKN Common Stock","published_at":"2019-11-26T16:33:50.000Z","date":"2019-11-22","kind":"grant","acquired":true,"shares":18293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents Restricted Stock Units issued to the recipient, in lieu of a portion of his Board compensation, on November 22, 2019 at the closing price of $2.46. The Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period."}],"balance_after":64694,"source":{"system":"sec-edgar","filing":"0001051514-19-000128","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1051514/000105151419000128/form4.xml","form_type":"4"}},{"id":3423683,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-09-04T16:19:43.000Z","date":"2019-09-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units, which vest in full on September 3, 2020, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001179110-19-010059","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000117911019010059/edgar.xml","form_type":"4"}},{"id":3489977,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:59:47.000Z","date":"2019-06-13","kind":"purchase","acquired":true,"shares":2000,"price":13.65,"value":27300.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001570562-19-000103","document":"wf-form4_156056397196003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056219000103/wf-form4_156056397196003.xml","form_type":"4"}},{"id":3489976,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option (right to buy)","published_at":"2019-06-14T16:18:23.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting."}],"balance_after":16000,"derivative":{"exercise_price":21.45,"exercise_date":"2019-07-12","expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-19-035670","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000110465919035670/a4.xml","form_type":"4"}},{"id":3492998,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Melinta Restricted Stock Units","published_at":"2019-06-12T13:37:15.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date."}],"balance_after":30000,"derivative":{"exercise_price":0,"underlying":"Melinta Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001461993-19-000031","document":"wf-form4_156036102095305.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000146199319000031/wf-form4_156036102095305.xml","form_type":"4"}},{"id":3686921,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-25T20:18:18.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":14500,"derivative":{"exercise_price":16.19,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001570562-19-000019","document":"wf-form4_154846548092960.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056219000019/wf-form4_154846548092960.xml","form_type":"4"}},{"id":3729778,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-17T21:51:35.000Z","date":"2018-12-14","kind":"purchase","acquired":true,"shares":3000,"price":12.7667,"value":38300.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $12.72 to $12.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001570562-18-000130","document":"wf-form4_154510147610889.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056218000130/wf-form4_154510147610889.xml","form_type":"4"}},{"id":3866547,"issuer":{"id":72980,"kind":"organization","name":"STRATA Skin Sciences, Inc.","symbol":"SSKN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-17T15:19:46.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":31401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Common Stock represents Restricted Stock Units issued to the recipient, in lieu of a portion of his Board compensation, on 6/8/18 at the closing price of $2.07. The Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period."},{"field":"shares","element":"transactionShares","label":"F2","text":"This amendment corrects the number of Restricted Stock Units granted. The amendment also moves the grant of the Restricted Stock Units from Table II to Table I."}],"balance_after":46401,"source":{"system":"sec-edgar","filing":"0001140361-18-032709","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036118032709/doc1.xml","form_type":"4/A","original_submission_date":"2018-06-11"}},{"id":3889167,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-19T16:42:20.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018."}],"balance_after":25000,"derivative":{"exercise_price":2.97,"expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-017191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924318017191/doc4.xml","form_type":"4"}},{"id":3894296,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-14T16:53:37.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":9100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018."}],"balance_after":9100,"derivative":{"exercise_price":7.45,"exercise_date":"2019-04-20","expiration_date":"2028-04-20","underlying":"Common Stock","underlying_shares":9100},"source":{"system":"sec-edgar","filing":"0000899243-18-016633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924318016633/doc4.xml","form_type":"4"}},{"id":3894295,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-14T16:53:37.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019.  The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019."}],"balance_after":25000,"derivative":{"exercise_price":7.45,"expiration_date":"2028-04-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-016633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924318016633/doc4.xml","form_type":"4"}},{"id":3898876,"issuer":{"id":72980,"kind":"organization","name":"STRATA Skin Sciences, Inc.","symbol":"SSKN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"STRATA Restricted Stock Units","published_at":"2018-06-11T18:18:01.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":26570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted Stock Options will vest 100%, in equal quarterly installments, over a 12 month period."}],"balance_after":26570,"derivative":{"exercise_price":2.07,"exercise_date":"2019-06-08","expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":26570},"source":{"system":"sec-edgar","filing":"0001140361-18-028130","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036118028130/doc1.xml","form_type":"4"}},{"id":3914351,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-30T16:38:26.000Z","date":"2018-05-25","kind":"purchase","acquired":true,"shares":5000,"price":6.09,"value":30450.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0000899243-18-014450","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924318014450/doc4.xml","form_type":"4"}},{"id":3956308,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-04-26T13:36:43.000Z","date":"2018-04-24","kind":"grant","acquired":true,"shares":22696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of February 12, 2018."}],"balance_after":22696,"derivative":{"exercise_price":8.01,"expiration_date":"2028-04-24","underlying":"Common Stock","underlying_shares":22696},"source":{"system":"sec-edgar","filing":"0001570562-18-000021","document":"wf-form4_152476415212778.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000157056218000021/wf-form4_152476415212778.xml","form_type":"4"}},{"id":4231041,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-17T17:00:22.000Z","date":"2017-08-16","kind":"purchase","acquired":true,"shares":3000,"price":1.813,"value":5439.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0000899243-17-020616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924317020616/doc4.xml","form_type":"4"}},{"id":4282492,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-14T17:00:26.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 13, 2017."}],"balance_after":25000,"derivative":{"exercise_price":1.7,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-17-016391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924317016391/doc4.xml","form_type":"4"}},{"id":4316201,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-17T17:00:46.000Z","date":"2017-05-16","kind":"purchase","acquired":true,"shares":3000,"price":1.68,"value":5040.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0000899243-17-013537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924317013537/doc4.xml","form_type":"4"}},{"id":4499160,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-05T21:56:01.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests on the following schedule: 1/12th of the shares vest monthly at the end of each month over 12 months, beginning after 01/01/2017."}],"balance_after":15000,"derivative":{"exercise_price":3,"expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-002491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000120919117002491/doc4.xml","form_type":"4"}},{"id":4503588,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-04T07:46:50.000Z","date":"2017-01-03","kind":"purchase","acquired":true,"shares":5000,"price":2.944,"value":14720.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-17-000499","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000120919117000499/doc4.xml","form_type":"4"}},{"id":4517280,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-19T17:05:43.000Z","date":"2016-12-16","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 22, 2016."}],"balance_after":10000,"derivative":{"exercise_price":1.58,"expiration_date":"2026-12-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-16-035947","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924316035947/doc4.xml","form_type":"4"}},{"id":4520753,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-15T17:15:16.000Z","date":"2016-12-15","kind":"purchase","acquired":true,"shares":3000,"price":1.65,"value":4950.0,"ownership":{"direct":true},"balance_after":8000,"source":{"system":"sec-edgar","filing":"0000899243-16-035625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924316035625/doc4.xml","form_type":"4"}},{"id":4520732,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-12-15T17:00:28.000Z","date":"2016-12-09","kind":"purchase","acquired":true,"shares":5000,"price":1.92,"value":9600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000899243-16-035615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000089924316035615/doc4.xml","form_type":"4"}},{"id":4543284,"issuer":{"id":180876,"kind":"organization","name":"EndoChoice Holdings, Inc.","symbol":"GI"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-11-23T10:21:49.000Z","date":"2016-11-22","kind":"disposition_to_issuer","acquired":false,"shares":53825,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger."},{"field":"security","element":"securityTitle","label":"F5","text":"This option was cancelled pursuant to the Merger.  Since the exercise price of this option exceeded the merger consideration of $8.00 per common shares, no value was received by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was cancelled pursuant to the Merger.  Since the exercise price of this option exceeded the merger consideration of $8.00 per common shares, no value was received by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger."}],"balance_after":0,"derivative":{"exercise_price":16.01,"expiration_date":"2025-08-14","underlying":"Common stock, par value $0.001 per share","underlying_shares":53825},"source":{"system":"sec-edgar","filing":"0001623919-16-000098","document":"wf-form4_147991449693774.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000162391916000098/wf-form4_147991449693774.xml","form_type":"4"}},{"id":4543283,"issuer":{"id":180876,"kind":"organization","name":"EndoChoice Holdings, Inc.","symbol":"GI"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-11-23T10:21:49.000Z","date":"2016-11-22","kind":"disposition_to_issuer","acquired":false,"shares":32230,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"This option was cancelled pursuant to the Merger in exchange for a cash payment representing the difference between the exercise price of the option and the merger consideration of $8.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled pursuant to the Merger in exchange for a cash payment representing the difference between the exercise price of the option and the merger consideration of $8.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger."}],"balance_after":0,"derivative":{"exercise_price":5.31,"expiration_date":"2026-03-29","underlying":"Common stock, par value $0.001 per share","underlying_shares":32230},"source":{"system":"sec-edgar","filing":"0001623919-16-000098","document":"wf-form4_147991449693774.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000162391916000098/wf-form4_147991449693774.xml","form_type":"4"}},{"id":4543282,"issuer":{"id":180876,"kind":"organization","name":"EndoChoice Holdings, Inc.","symbol":"GI"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common stock, par value $0.001 per share","published_at":"2016-11-23T10:21:49.000Z","date":"2016-11-22","kind":"disposition_to_issuer","acquired":false,"shares":38585,"price":8,"value":308680.0,"ownership":{"direct":false,"nature":"By David N. Gill & Diane P. Gill Joint Living Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"From April 1, 2016 through and including November 14, 2016, the reporting person transferred directly held shares to his indirectly held joint living trust, which resulted in a decrease in direct shares held and an increase in indirect shares held."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the \"Merger\"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001623919-16-000098","document":"wf-form4_147991449693774.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000162391916000098/wf-form4_147991449693774.xml","form_type":"4"}},{"id":4543281,"issuer":{"id":180876,"kind":"organization","name":"EndoChoice Holdings, Inc.","symbol":"GI"},"owners":[{"id":46555,"kind":"person","name":"GILL DAVID N","position":1,"cik":"0001106519","reported_name":"GILL DAVID N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common stock, par value $0.001 per share","published_at":"2016-11-23T10:21:49.000Z","date":"2016-11-22","kind":"disposition_to_issuer","acquired":false,"shares":125445,"price":8,"value":1003560.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"From April 1, 2016 through and including November 14, 2016, the reporting person transferred directly held shares to his indirectly held joint living trust, which resulted in a decrease in direct shares held and an increase in indirect shares held."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the \"Merger\"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001623919-16-000098","document":"wf-form4_147991449693774.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106519/000162391916000098/wf-form4_147991449693774.xml","form_type":"4"}}]}